These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 7656506)

  • 1. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity.
    Ujhelyi MR; Robert S
    Clin Pharmacokinet; 1995 Jun; 28(6):483-93. PubMed ID: 7656506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin.
    Ujhelyi MR; Robert S; Cummings DM; Colucci RD; Green PJ; Sailstad J; Vlasses PH; Zarowitz BJ
    Ann Intern Med; 1993 Aug; 119(4):273-7. PubMed ID: 8328735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of digoxin immune Fab in patients with kidney failure.
    Ujhelyi MR; Robert S; Cummings DM; Colucci RD; Sailstad JM; Vlasses PH; Findlay JW; Zarowitz BJ
    Clin Pharmacol Ther; 1993 Oct; 54(4):388-94. PubMed ID: 8222481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digoxin intoxication in a patient with end-stage renal disease: efficacy of digoxin-specific Fab antibody fragments and peritoneal dialysis.
    Caspi O; Zylber-Katz E; Gotsman O; Wolf DG; Caraco Y
    Ther Drug Monit; 1997 Oct; 19(5):510-5. PubMed ID: 9357092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment.
    Allen NM; Dunham GD; Sailstad JM; Findlay JW
    DICP; 1991 Dec; 25(12):1315-20. PubMed ID: 1815424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon.
    Smith TW; Lloyd BL; Spicer N; Haber E
    Clin Exp Immunol; 1979 Jun; 36(3):384-96. PubMed ID: 114346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digoxin-specific antibody fragments in the treatment of digoxin toxicity.
    Chan BS; Buckley NA
    Clin Toxicol (Phila); 2014; 52(8):824-36. PubMed ID: 25089630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma exchange for the removal of digoxin-specific antibody fragments in renal failure: timing is important for maximizing clearance.
    Zdunek M; Mitra A; Mokrzycki MH
    Am J Kidney Dis; 2000 Jul; 36(1):177-83. PubMed ID: 10873888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of digoxin-specific Fab fragments for severe digitalis intoxication in children.
    Woolf AD; Wenger T; Smith TW; Lovejoy FH
    N Engl J Med; 1992 Jun; 326(26):1739-44. PubMed ID: 1594015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digitalis intoxication and treatment with digoxin antibody fragments in renal failure.
    Erdmann E; Mair W; Knedel M; Schaumann W
    Klin Wochenschr; 1989 Jan; 67(1):16-9. PubMed ID: 2921838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digoxin elimination in a functionally anephric patient after digoxin-specific Fab fragment therapy.
    Nuwayhid NF; Johnson GF
    Ther Drug Monit; 1989 Nov; 11(6):680-5. PubMed ID: 2595749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-related differences in digoxin toxicity and its treatment.
    Wells TG; Young RA; Kearns GL
    Drug Saf; 1992; 7(2):135-51. PubMed ID: 1605899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The plasma disposition and renal elimination of digoxin-specific Fab fragments and digoxin in the rabbit.
    Timsina MP; Hewick DS
    J Pharm Pharmacol; 1992 Oct; 44(10):796-800. PubMed ID: 1360503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring serum digoxin concentrations during digoxin immune Fab therapy.
    Ujhelyi MR; Colucci RD; Cummings DM; Green PJ; Robert S; Vlasses PH; Zarowitz BJ
    DICP; 1991 Oct; 25(10):1047-9. PubMed ID: 1803787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age.
    Renard C; Grene-Lerouge N; Beau N; Baud F; Scherrmann JM
    Br J Clin Pharmacol; 1997 Aug; 44(2):135-8. PubMed ID: 9278197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute digoxin overdose in a newborn with renal failure: use of digoxin immune Fab and peritoneal dialysis.
    Berkovitch M; Akilesh MR; Gerace R; Verjee Z; McGuigan M; Whyte H; Koren G
    Ther Drug Monit; 1994 Oct; 16(5):531-3. PubMed ID: 7846755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antidigoxin Fab fragments and digoxin monitoring: a challenge for the biologist].
    Parant F; Ducluzeau R; Lardet G; Gagnieu MC; Moulsma M
    Ann Biol Clin (Paris); 2003; 61(6):645-53. PubMed ID: 14711605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The monitoring of plasma digoxin levels during acute digitalis poisoning treated with Fab anti-digoxin fragments].
    Milani L; Bizzaro N; Sanson A
    G Ital Cardiol; 1992 Jan; 22(1):97-101. PubMed ID: 1624074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interspecies scaling of clearance and volume of distribution for digoxin-specific Fab.
    Grene-Lerouge NA; Bazin-Redureau MI; Debray M; Scherrmann JM
    Toxicol Appl Pharmacol; 1996 May; 138(1):84-9. PubMed ID: 8658517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with digoxin immune Fab (ovine) in patients with renal impairment.
    Wenger TL
    Am J Emerg Med; 1991 Mar; 9(2 Suppl 1):21-3; discussion 33-4. PubMed ID: 1997017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.